ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.050.00%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · SPRY
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 116.9 | 84.3 | 89.1 | 0.0 | 1.3 | 5.5 | — |
| Cost of Revenues | — | — | — | 0.0 | — | — | — |
| Operating Expenses & Income | |||||||
| Selling, General & Admin | 284.5 | 230.1 | 71.7 | 47.3 | 0.6 | — | — |
| R&D Expenses | 15.2 | 13.2 | 19.6 | 20.3 | 18.4 | 20.3 | 24.6 |
| Operating Income | (216.3) | (179.4) | (3.1) | (67.5) | (35.5) | (19.5) | (32.9) |
| Earnings from Continuing Operations | |||||||
| Other Non-Operating Income / Expenses | — | — | — | — | 0.8 | (0.8) | — |
| EBT, Incl. Unusual Items | — | (171.4) | 8.3 | (54.4) | — | — | — |
| Income Tax Expense | — | (0.1) | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (215.4) | (171.3) | 8.0 | (54.4) | (34.7) | (20.2) | (32.9) |
| Per Share | |||||||
| Basic EPS | (2.17) | (1.74) | 0.08 | (0.57) | (0.87) | (0.70) | — |
| Diluted EPS | (2.17) | (1.74) | 0.08 | (0.57) | (0.87) | (0.70) | — |
| Revenue per Share | 1.18 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 99.3 | 98.6 | 96.9 | 95.2 | 40.0 | 28.9 | — |
| Diluted Weighted Avg Shares | 99.3 | 98.6 | 102.4 | 95.2 | 40.0 | 28.9 | — |
| Supplemental | |||||||
| EBITDA | — | (178.1) | (3.0) | (67.4) | (35.4) | (19.2) | — |
| EBIT | (216.3) | (179.4) | (3.1) | (67.5) | (35.5) | (19.5) | (32.9) |
| Effective Tax Rate | — | — | — | 0.0% | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.